Original title: Sino-American Huashitong launched listing tutoring founder former pharmaceutical giant Eli Lilly and Co senior scientist source: IPO knew
It is reported that Sino-American Huashitong Biopharmaceutical Technology (Wuhan) Co., Ltd. (hereinafter referred to as "Sino-American Huashitong")Everbright Securities(quote 601788) signed a listing counseling agreement, and recently filed with Hubei Securities Regulatory Bureau.
Founded in 2009, Huashitong is mainly engaged in the R & D and production of macromolecular drugs for diabetes and nephropathy, focusing on bone and muscle drugs, digestive system drugs, antivirals and new biotechnology drugs. With a polymer innovative drug screening platform, four drugs are expected to enter the clinical stage one after another.
At present, Sino-American Huashitong has established four production lines of polymer drugs from intermediates, raw materials to high-end preparations, and is the largest local intermediate supplier to international pharmaceutical companies for nephrotic hyperkalemia and hyperphosphatemia. The sales of key products of Sino-American Huashitong exceeded 100 million yuan in 2019 and 2020.
According to the company's website, Sino-American Huashi received $24 million in round B financing in 2012. According to APP, Sino-American Huashi announced the completion of 420 million yuan C round financing in August 2020.Led by the national investment force, Panxi CapitalProduction, Yuansheng Venture Capital, Merchants Zhiyuan Capital and Huide Fusion Industrial Fund. Just three months later, in December 2020, Sino-American Huashi was awarded theVega CapitalThe 100 million yuan C + round financing led by the former shareholderChina Merchants Zhiyuan Capital and Dexin Huifu Fund continue to follow..
Data show that Weigao Capital is a health industry fund jointly initiated by Weigao Group and Shandong State-owned assets Investment Holdings Co., Ltd., in order to develop the financial industry on the basis of existing industries and realize the interaction between industry and finance of Weigao Group. promote regional and local development.
It is worth mentioning that Weigao Blood purification products Co., Ltd., an industry-wide subsidiary of Shandong Weigao Group Medical Polymer (01066.HK) that provides blood purification treatment-related products and services, has recently entered the guidance period of listing; Science and Technology Innovation Board IPO of another subsidiary, Weigao Orthopaedics, is also under inquiry.
Zhang Sheng, founder and CEO of Huashitong, China and the United States, previously said that Vega, as a well-known domestic medical device and drug production and sales enterprise, has a business scope across orthopaedic, nephrotic, cardiovascular and other diseases, and is a leader in the domestic blood purification industry. C + round financing introduced Vega as a strategic investor for both sides to further deepenThe field of nephropathy treatmentThe cooperation and market expansion have laid the foundation.
Zhang Ming graduated from Wuhan University, Chinese Academy of Sciences and Southwest Medical Center of the University of Texas.He used to be a senior scientist of American pharmaceutical giant Eli Lilly and Co.And Director of New Drug Research and Development.